RoslinCT, a cell and gene therapy contract development and manufacturing organization (CDMO), will manufacture the first ever U.S. FDA approved CRISPR-based gene therapy. CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, was approved by the FDA in December 2023 for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).  RoslinCT and Vertex have worked closely on an adaptive basis as Vertex...